{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "FTRE", "name": "Fortrea Holdings Inc.", "url": "https://orbyd.app/dossiers/FTRE/", "json_url": "https://orbyd.app/dossiers/FTRE.json", "status": "DORMANT", "current_conviction": "MEDIUM", "graded_conviction": null, "archetype": { "code": "a4", "n": 4 }, "current_thesis": "Q2 (2026-07-29) beat and lifted the FY26 floor — adj EPS $0.23 vs $0.18, revenue $678.2M vs $647.5M, EBITDA guide to $205–220M — and four target raises to $22–26 followed. But the whole earnings week was given back by 7/31 ($19.17 vs $19.20 on 7/27) after a $21.39 high, with revenue still −4.5% YoY against double-digit peer growth. Fundamentals improved; the bid did not.", "invalidation_trigger": "A weekly close below $17 forfeits the 2026-07-20/22 breakout shelf and the rising 50-day; secondary breaks: trailing-twelve-month book-to-bill slips under 1.0x from 1.12x, or the raised FY26 adjusted-EBITDA floor is cut at the Q3 print (~early November 2026).", "catalyst_date": "2026-08-05", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "binary-catalyst-biotech", "consumer-discretionary-rotation", "precision-biotech-therapeutics" ], "tags": [], "sources": [], "notes": [ "Fortrea is a CRO spun from Labcorp in July 2023 — clinical-trial services, not a drug developer and not managed care. Theme screens routinely mis-tag it.", "A securities class action filed in 2025 over post-spin 2025 EBITDA targets and projected TSA exit savings remains unresolved.", "Leverage is structural: long-term debt $1,037.2M at 2026-06-30; term loan A matures 2028-06-30, term loan B 2030-06-30, 7.500% secured notes due 2030.", "Customer concentration is high: top-10 customers were 55.4% of Q2 2026 revenue and the largest was 16.8%; one cancellation moves backlog materially.", "Q3 2026 results are expected ~early November 2026. The 2026-08-05 date some data providers still list was superseded by the 2026-07-29 release." ], "body_markdown": "## Current Thesis\n\nThe binary this dossier has been pointing at since May resolved — a week earlier than the calendar said. Fortrea reported Q2 2026 on **2026-07-29**, not the 2026-08-05 date several data providers still carry, and it resolved in the bulls' favour on the numbers: adjusted EPS $0.23 against a $0.18 consensus, revenue $678.2M against $647.465M consensus, and a raised FY26 guide — revenue to $2.620–2.690B from $2.550–2.650B (consensus $2.607B), adjusted EBITDA to $205–220M from $190–220M. Four target raises landed inside 48 hours: Truist Buy $26 and Evercore ISI Outperform $25 and Barclays Equal-Weight $22 on 2026-07-30, Citi Buy $22 on 2026-07-31. The margin-of-safety picture inverted from the July note: the ~$20.18 average target across 12 analysts now sits **above** spot, where in early July spot sat above the median.\n\nThe narrative leg being bought is unchanged in kind and weaker in degree — margin repair plus a bookings recovery converting into revenue on a lag. What changed is that the second engine sputtered. Book-to-bill fell to 1.06x from 1.15x in Q1; backlog slipped to $7.800B at 2026-06-30 from $7.846B at 2026-03-31; adjusted EBITDA went $54.9M → $58.7M year over year, a fraction of Q1's +55.1% pace. The guide raise was a floor raise: the $220M ceiling was left untouched.\n\nAnd the price did not confirm. Closes ran $19.20 (7/27), $20.70 (7/28), $20.40 (7/29), $19.08 (7/30), $19.17 (7/31) — the entire earnings-week advance returned in three sessions, with a 52-week high of $21.39 left overhead and volume fading from 3.24M and 3.16M shares on 7/28–29 to 1.95M and 1.91M on 7/30–31. Best print since the spin, four target hikes, and the close on 7/31 was three cents below where it sat before any of it.\n\n**Life-cycle: MATURING.** Dated by the 2026-07-29 print (book-to-bill 1.15x → 1.06x, backlog down QoQ, EBITDA growth decelerating) and the 7/28–7/31 round-trip that absorbed the year's best headline without a new closing high.\n\n## Bull Case\n\n- **Q2 2026 (2026-07-29) beat on both lines** — adjusted EPS $0.23 vs $0.18 consensus; revenue $678.2M vs $647.465M consensus; adjusted EBITDA $58.7M against $54.9M in Q2 2025.\n- **The guide floor moved up, not just the revenue band** — FY26 adjusted EBITDA raised to $205–220M from $190–220M and revenue to $2.620–2.690B from $2.550–2.650B (2026-07-29), with the revenue midpoint now above the $2.607B consensus.\n- **Fourth consecutive quarter of book-to-bill above 1.0x** — 1.06x in Q2, 1.12x trailing twelve months, on $720.4M of net new business weighted toward biotech; first-half net new business awards were up 19% YoY (Q2 call, 2026-07-29).\n- **Cost-out is landing in the P&L** — $18M of new gross savings in Q2, $34M gross and $19M net year to date (Q2 call, 2026-07-29).\n- **Cash generation turned** — Q2 operating cash flow $28.9M and free cash flow $19.9M; no revolver borrowings in H1 2026; approximately 35% of original post-spin debt repaid, with management guiding to positive free cash flow through the rest of 2026 (2026-07-29).\n- **Sell-side re-anchored above the tape** — the 12-analyst average target of ~$20.18 sits above the $19.17 close of 2026-07-31, with a $26 high (Truist, 2026-07-30). In early July the relationship ran the other way.\n- **The end market is funding again** — IQVIA cited roughly $25B of early-stage biopharma funding in Q1 2026, near double the year-earlier level; sector RFP flow has followed.\n\n## Bear Case\n\n- **Revenue is still contracting while the peer group grows** — Q2 revenue $678.2M, −4.5% YoY from $710.3M; H1 $1,314.7M, −3.4% YoY. Medpace reported Q2 2026 revenue of $707.3M, +17.2% YoY, on a 1.13x book-to-bill; IQVIA reported $4.37B and raised its full-year guide. Fortrea is shrinking inside a recovering end market, which makes the gap company-specific rather than cyclical.\n- **Operating leverage decelerated sharply** — Q1 adjusted EBITDA grew 55.1% YoY; Q2's move was $54.9M to $58.7M. The unchanged $220M FY ceiling says management did not extend the upper bound after the beat.\n- **Backlog went the wrong way and burn quality is mixed** — $7.846B (2026-03-31) → $7.800B (2026-06-30), with Q2 burn at 8.6%, higher sequentially and attributed to clinical-pharmacology service-fee growth and increased passthrough revenue (Q2 call, 2026-07-29).\n- **Still GAAP-lossmaking** — Q2 net loss $(13.2)M, or $(0.14) per diluted share; FY2025 net loss $986.2M.\n- **Leverage is the structural constraint** — long-term debt less current portion of $1,037.2M at 2026-06-30 (Q2 10-Q), total debt $1.12B against $168.6M cash, a net debt position of about $949.2M, debt/equity near 1.98 and a current ratio of 0.95. Term loan A matures 2028-06-30, term loan B 2030-06-30; $494.257M of 7.500% senior secured notes due 2030 remain after the tender that retired $75.743M.\n- **Concentration** — top-10 customers were 55.4% of Q2 revenue, the largest single customer 16.8% (Q2 call, 2026-07-29). One programme cancellation moves the backlog line by itself.\n- **Trailing valuation is no longer the low bar it was** — enterprise value ~$2.77B against a FY26 adjusted-EBITDA guide of $205–220M, with trailing EV/EBITDA at roughly 41x.\n- **Insider supply into strength** — COO Mark A.\n\n## Setup & Price Structure\n\nClose $19.17 on 2026-07-31, roughly 10% under the $21.39 top of the $5.27–$21.39 52-week range. The 50-day sits near $16.68 and the 200-day near $13.77 (late-July readings), both rising — price is roughly 15% above the 50-day and close to 40% above the 200-day, so the trend structure is intact and the entry is extended relative to it.\n\nThe base that matters is the 2026-07-20 to 2026-07-22 congestion at $17.73–$18.49, which preceded the run to a $20.19 intraday high on 2026-07-23 and the post-print $21.39. The failure sequence is legible: two closes above $20 on 3.2M-share sessions, then two closes back near $19 on roughly 1.9M shares. Losing $19 puts price back inside that July shelf; losing $17 gives the shelf up entirely and brings the rising 50-day into play.\n\nCrowding observables, stated as observables: short interest of 10.26M shares, about 10.9% of float and 7.18 days to cover; beta of 1.95; market cap $1.82B on 95.10M shares. A double-digit short base against the best print since the spin produced two up-closes and no follow-through — that is the participation datapoint, and it is the reason this is not labelled ACCELERATING despite the headline density of 2026-07-29 through 2026-07-31. There is no company-scheduled event to force the issue for roughly three months.\n\n## Catalyst Calendar (next 30 days)\n\n- **Through 2026-08-31: nothing company-scheduled.** The Q2 print landed 2026-07-29; the 2026-08-05 date still shown by some data providers is dead and should not be treated as a pending event.\n- **~2026-08-12 and ~2026-08-26 (est.)**: FINRA semi-monthly short-interest publications — the first reads on whether the ~10.9%-of-float short base covered into the beat or was rebuilt into the fade.\n- **~February 2027 (est.)**: FY2026 results and the initial FY2027 outlook — where the walk toward the company's mid-teens long-term margin target either gets a number attached or does not.\n\n## Elapsed catalysts\n\n- **~early November 2026 (est.)**: Q3 2026 results, the first guidance-setting print for CFO Jason Knoblauch (effective 2026-07-06) and the first hard test of the raised $205M adjusted-EBITDA floor and of whether book-to-bill holds above 1.0x for a fifth quarter. *(passed 34d ago)*\n\n## What Would Change Our Mind\n\nThe leg rests on one bridge: bookings converting into revenue growth before the cost-out runs dry. Two things would show the bridge failing. First, structure — **a weekly close below $17** forfeits the 2026-07-20/22 breakout shelf and the rising 50-day, converting the July–August range into a distribution top rather than a pause; a weekly close below $19 is the earlier warning that the post-print fade is extending rather than basing. Second, the operating series — trailing-twelve-month book-to-bill slipping under 1.0x from the current 1.12x, backlog falling for a second straight quarter from $7.800B, or the raised $205M adjusted-EBITDA floor being walked back at the Q3 print, would remove the reason the multiple expanded at all.\n\nThe theme flips to SATURATED if Q3 delivers another revenue decline against double-digit growth at Medpace and IQVIA — at that point the story is share loss inside a recovering market, and the $22–26 target cluster set on 2026-07-30/31 becomes the marker of peak sell-side enthusiasm.\n\nWhat would rebuild conviction: a Q3 book-to-bill back at or above 1.15x with backlog turning up, revenue decline narrowing toward flat, and a close above $21.39 on volume exceeding the 3.2M-share earnings-session prints.\n\n## Correlation Notes\n\nFTRE trades within the clinical-trial-services complex — IQVIA, ICON, Medpace, Charles River, and Thermo Fisher's PPD unit — and takes sector-wide direction from biopharma R&D budget headlines, biotech financing windows, and drug-pricing and NIH-funding policy. The 2026 Q2 season split that group: IQVIA at $4.37B revenue with a raised guide and Medpace at $707.3M, +17.2% YoY, versus Fortrea at −4.5% YoY. Sector beta will lift FTRE on funding headlines; the idiosyncratic spread is execution and share.\n\nBookings skew matters for correlation: the $720.4M of Q2 net new business was described as weighted toward biotech (2026-07-29), which ties the order book to small- and mid-cap biotech financing conditions rather than to large-pharma budget stability. Net debt of roughly $949.2M against $168.6M of cash adds a rates channel — the equity is levered to both the funding cycle and the discount rate applied to a sub-10% EBITDA margin.\n\nOne classification note that repeatedly distorts screens: Fortrea is a contract research organisation spun out of Labcorp in July 2023. It is not a drug developer and not a managed-care name, and it carries no clinical-readout binaries of its own.", "first_seen": "2026-05-06", "last_analyzed": "2026-08-01T09:18:28+00:00", "last_synthesized": "2026-08-01", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }